Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2022

Efficacité comparative du guselkumab dans le rhumatisme psoriasique: Mises à jour d'une revue systématique de la littérature et d'une méta-analyse en réseau

Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac500

Tam LS,

Guselkumab (GUS) demonstrates better skin efficacy than most other targeted PsA therapies, including upadacitinib. The objective of this NMA update was to expand the network to include all targeted therapies in PsA on arthritis, skin efficacy and safety, and to include data on GUS patients with an IR to TNFinibs.

Keywords:

September 2022

Upadacitinib en monothérapie et en association avec des antirhumatismaux modificateurs de la maladie non biologiques dans le traitement du rhumatisme psoriasique

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab905

Nash P,

Kato K,

McDearmon-Blondell EL,

Feng D,

In this investigation, upadacitinib showed comparable efficacy as monotherapy and in combination with nbDMARDs in PsA. In coming to this conclusion investigators aimed to assess the efficacy and safety of upadacitinib as monotherapy or in combination with nbDMARDs in patients with PsA.

Keywords:

August 2022

Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

Arthritis Rheumatol 2022 doi: 10.1002/art.42280

Ink B,

In this investigation bimekizumab was associated with a sustained ACR50 improvement. This was highlighted following the attempt to describe the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients

Keywords:

July 2022

Le guselkumab offre une efficacité durable, spécifique à un domaine et globale, selon des indices composites, chez les patients atteints de rhumatisme psoriasique actif

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac375

Xu XL,

Shawi M,

Karyekar CS,

Contré C,

Noël W,

Sheng S,

Wang Y,

Xu S,

Mease PJ

This analysis found that patients with active PsA who receive treatment with guselkumab can achieve robust and sustained low disease activity or remission. In reaching this conclusion investigators sought to evaluate the efficacy of guselkumab for the treatment of active PsA through the use of composite indices.